Projet OLIGOMED (Horizon 2020, appel à projets 2020)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : SIGNED

The use of synthetic oligonucleotides (ONs, short DNA or RNA strands) in the treatment of genetic diseases is a rapidly growing field, and the most promising alternative to gene therapy or small molecules. Most pharmaceutical companies shift from in-house platform development to product-specific licensing and co-development to get ON based therapies past clinical trials. Therefore there is a growing and currently unmet need for a combined academic and industry-based multidisciplinary research to further advance the field by bringing together the separated and fragmented R&D efforts of diverse ON technologies. OLIGOMED will address these needs by: - uniting world-class academic and private sector expertise in ON chemistry, bio-analysis and medical applications - developing a next generation ON platform technology based on combining tailored synthetic ONs with smart delivery - optimising ON therapies through testing in medicinal environments We will use these novel ON technologies to develop innovative treatment options for high-impact genetic diseases, i.e. Huntington’s disease, cardiovascular diseases and cancer. Our European intersectoral and multidisciplinary research and training network for 15 Early Stage Researchers (ESRs) will deliver: -highly skilled scientific staff required to fully exploit ON therapeutics for personalised medicine -top-class training in organic and chemoenzymatic synthesis, ON analysis, and biomedical/medicinal testing -transferable skills courses, specific industry relevant workshops and public engagement activities This combination makes OLIGOMED a truly exciting programme for ESRs. The platform will immediately benefit to both European citizens and commercial partners. In the long term, OLIGOMED`s flexible platform technology will be taken forward by our private sector and research institutions for exploitation and will thus strengthen the European innovation capacity in the field of ON therapies.

Mots clés : dna chemistry, modified nucleotide, on therapy, dna origami, transfection, huntington s disease, cancer, gene analysis, gene silencing, imaging, delivery, chemoenzymatic synthesis, directed evolution

Participants :
- Centre national de la recherche scientifique (France) — Partner, beneficiary, Recherche, subvention : 274802.04 €
- University of Udine (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 348666.24 €
- Krzysztof kucharczyk techniki elektroforetyczne spzoo (Pologne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 56869.65 €
- Karolinska Institutet (Suède) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 281982.96 €
- AstraZeneca (Sweden) (Suède) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 281982.96 €
- University of Cambridge (Royaume-Uni) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 303172.56 €
- University of Southampton (Royaume-Uni) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 606345.12 €
- Sixfold bioscience ltd (Royaume-Uni) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 303172.56 €
- International institute of molecular mechanisms and machines polish academy of sciences (Pologne) — Partner, beneficiary, Recherche, subvention : 151652.4 €
- Polish Academy of Sciences (Pologne) — Partner, beneficiary, Recherche, subvention : 170608.95 €
- RISE Research Institutes of Sweden (Suède) — Partner, beneficiary, Recherche, subvention : 281982.96 €
- Institut national de la santé et de la recherche médicale (France) — Partner, beneficiary, Recherche, subvention : 274802.04 €
- Ghent University (Belgique) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 512640.0 €
- Stockholm County Council (Suède) — Partner, beneficiary, Organismes publics (hors enseignement & recherche), subvention : 281982.96 €